Dr. Hessa Alotaibi is a Consultant Neurologist at King’s College Hospital in Jeddah, bringing over 24 years of extensive experience in neurology. She is renowned for her expertise in diagnosing and treating a wide range of neurological conditions. Dr. Hessa earned her medical degree from King Abdulaziz University in Jeddah and holds board certifications in both Internal Medicine and Neurology from the Saudi Board.
Her distinguished career includes serving as the Head of the Neurology Department at King Fahd Hospital for many years. In addition to her clinical work, Dr. Hessa has played a pivotal role in advancing the field of neurology, acting as the Program Director and Regional Chairperson for the Saudi Neurology Board in the Western Region. She is also an active member of the Scientific Councils within the Saudi Neurology Board.
Dr. Hessa’s clinical interests encompass multiple sclerosis, acute and chronic stroke, parkinsonism, epilepsy, migraine, and dementia, with a particular focus on multiple sclerosis. She has extensive experience in treating MS patients and has contributed to several research initiatives aimed at improving diagnosis and management.
Committed to the highest standards of patient care, Dr. Hessa is passionate about continuing education and advancing the field of neurology through both research and hands-on patient care.
1- Saudi Consensus Recommendations on the Management of Multiple Sclerosis:
Disease-Modifying Therapies and Management of Relapses December 2022
Clinical and Translational Neuroscience 6(4): 27
2- Saudi Consensus Recommendations on the Management of Multiple Sclerosis:
Symptom Management and Vaccination
Clin. Transl. Neurosci. 2023, 7(1), 6; https://doi.org/10.3390/ctn7010006
3- Association between obesity during different age periods and multiple sclerosis in
Saudi Arabia: A multi-center case-control study April 2022Neurosciences
27(2):87-93
4- Prevalence of Pediatric Onset Multiple Sclerosis in Saudi Arabia November 2021
Multiple Sclerosis International 2021(2):1-6
5- Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia
May 2021 Multiple Sclerosis and Related Disorders 52(4):103004
6- Real-world retrospective study of effectiveness and safety of Fingolimod in relapsing
remitting multiple sclerosis in the Middle East and North Africa (FINOMENA)
February 2021 Clinical Neurology and Neurosurgery 203:106576
7- Familial aggregation of multiple sclerosis: Results from the national registry of the
disease in Saudi Arabia October 2020 Multiple Sclerosis Journal – Experimental
Translational and Clinical 6(4):205521732096049
8- Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study
February 2020 BMC Neurology 20(1)
9- Environmental exposures and the risk of multiple sclerosis in Saudi Arabia
June 2018 BMC Neurology 18(1):86
10- Neuromyelitis Optica Spectrum Disorder: A Rare Case of Transverse Myelitis and
Autonomic Dysfunction DOI: 10.7759/cureus.38791
11- The Saudi Arabian National Multiple Sclerosis Registry (NMSR): Initial Results
Saudi MS Registry Study Group* (P2.390) | Neurology:
https://www.neurology.org/doi/10.1212/WNL.90.15_supplement.P2.390
